Open AccessNovel Therapeutics for the Treatment of Burn Infection
Author(s) -
Christen E Salyer,
Christina Bomholt,
Nadine Beckmann,
Christian B. Bergmann,
Courtney A. Plattner,
Charles C. Caldwell
Publication year - 2021
Publication title -
surgical infections
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.773
H-Index - 60
eISSN - 1557-8674
pISSN - 1096-2964
DOI - 10.1089/sur.2020.104
Subject(s) - medicine , burn injury , immune system , intensive care medicine , antimicrobial , immunotherapy , immunology , clinical trial , microbiology and biotechnology , surgery , biology
Background: Burn injury continues to be a significant cause of morbidity and death, with infectious complications being the primary cause of death. Patients are susceptible to overwhelming infection secondary to both the physical breakdown of the skin and mucosal barrier and the immune dysfunction that accompanies the inflammatory response to a major burn. With resistance to traditional antibiosis looming as a serious threat to patient outcome, advancement in the treatment of burn infections is imperative. Methods: Between February 15 and March 15, 2020, a search of Pubmed and clinicaltrials.gov was performed using search terms such as "burn immunotherapy," "therapeutic microorganisms in burn," "burn infection clinical trials," and applicable variations. Results: Topical antimicrobial drugs continue to be standard of care for burn wound injuries, but personalized and molecular treatments that rely on immune manipulation of the host show great promise. We discuss novel therapeutics for the treatment of burn infection: Probiotics and therapeutic microorganisms, immune modulators, tailored monoclonal antibodies, and extracellular vesicles and proteins. Conclusions: The treatment strategies discussed employ manipulation of structure and function in host immune cells and pathogen virulence for improved outcomes in burn infection.